INDEGENE LIMITED
Momentum (71/100) does the heavy lifting; financial trend (40/100) is the drag.
Buy zoneOur blended model reads INDEGENE LIMITED as a Hold at 56/100. We put fair value near ₹562.83; at ₹608.95 that leaves roughly 8% downside, so the stock screens fairly valued. On 29.7x trailing earnings it sits cheaper than the Healthcare median of about 37.4x. It's trading right at its 52-week high of ₹611.65. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹605.29 implies about 1% downside across 7 analysts. It clears 9 of 14 investability checks, with durability 58, valuation 70 and momentum 71 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹450.27.
Analyst views
1-year price
EOD · 2026-09-2552-week range
-0.44% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold56Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 13.9%
- Pass: Low debt (D/E < 0.5): 0.05x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 33%
- Fail: Earnings growing: -32%
- Pass: Net margin ≥ 10%: 11.4%
- Pass: Current ratio > 1.5: 2.41
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- Pass: Positive 1-year return
- Pass: Altman Z in safe zone: Z 6.51
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter55.7%
- Institutions20.7%
- Public & other23.7%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Trading near its 52-week high.
- Financially solid — Altman Z 6.51.
Opportunities
- Revenue growing (33% YoY).
- Trading in our value buy zone versus sector peers.
Bear case
Threats
- Earnings contracting year on year.
About INDEGENE LIMITED
Indegene Limited provides digital-first commercialization services to life sciences companies across India, the United States, Europe, and other markets. The company operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, and Omnichannel Activation & Others, serving biopharmaceutical firms, emerging biotech companies, and medical device manufacturers.
INDEGENE LIMITED — frequently asked questions
Is INDEGENE LIMITED a buy, hold or sell?
StocksWizard currently rates INDEGENE LIMITED (INDGN) a Hold, based on a blended score of 56/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is INDEGENE LIMITED's fair value?
Our blended DCF and relative-valuation model estimates INDEGENE LIMITED's fair value at about ₹562.83, versus a current price of ₹608.95 — roughly 8% downside. On that basis the stock looks fairly valued.
Is INDEGENE LIMITED financially healthy?
INDEGENE LIMITED scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has INDEGENE LIMITED's share price performed?
INDEGENE LIMITED is up 7% over the past year and up 16% over three months, and last traded at ₹608.95. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.